Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

3,4-DAA

😃Good
Catalog No. T22506Cas No. 2117759-07-4

3,4-DAA has anti-inflammatory activity, ameliorates acute hepatic allograft injury, and alleviates severe acute pancreatitis by inhibiting intestinal barrier dysfunction and NF-κB activation.3,4-DAA inhibits EOC20 cell-inducible nitric oxide synthase (iNOS) induced by IFN-γ and lipopolysaccharide.

3,4-DAA

3,4-DAA

😃Good
Catalog No. T22506Cas No. 2117759-07-4
3,4-DAA has anti-inflammatory activity, ameliorates acute hepatic allograft injury, and alleviates severe acute pancreatitis by inhibiting intestinal barrier dysfunction and NF-κB activation.3,4-DAA inhibits EOC20 cell-inducible nitric oxide synthase (iNOS) induced by IFN-γ and lipopolysaccharide.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
5 mg$3454-6 weeks4-6 weeks
10 mg$5894-6 weeks4-6 weeks
50 mg$2,0504-6 weeks4-6 weeks
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Appearance:Solid
Color:Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
3,4-DAA has anti-inflammatory activity, ameliorates acute hepatic allograft injury, and alleviates severe acute pancreatitis by inhibiting intestinal barrier dysfunction and NF-κB activation.3,4-DAA inhibits EOC20 cell-inducible nitric oxide synthase (iNOS) induced by IFN-γ and lipopolysaccharide.
In vitro
3,4-DAA can alleviate the severity of colitis by inhibiting the response of Th1 cells, promoting the expression of Th2 cytokines, and inducing the expression of CD4(+)CD25(+) T cells[1].
In vivo
3,4-DAA is an orally active synthetic derivative of the tryptophan metabolite anthranilic acid, which can reverse paralysis in mice with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS)[1].
Chemical Properties
Molecular Weight343.33
FormulaC18H17NO6
Cas No.2117759-07-4
SmilesO=C(O)C=1C=CC=C(O)C1NC(=O)C=CC2=CC=C(OC)C(OC)=C2
Relative Density.no data available
Storage & Solubility Information
Storagestore at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 5 mg/mL (14.56 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.9126 mL14.5632 mL29.1265 mL145.6325 mL
5 mM0.5825 mL2.9126 mL5.8253 mL29.1265 mL
10 mM0.2913 mL1.4563 mL2.9126 mL14.5632 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy 3,4-DAA | purchase 3,4-DAA | 3,4-DAA cost | order 3,4-DAA | 3,4-DAA chemical structure | 3,4-DAA in vivo | 3,4-DAA in vitro | 3,4-DAA formula | 3,4-DAA molecular weight